{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:36:51Z","timestamp":1787243811503,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118497","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:52:31Z","timestamp":1756367551000},"page":"118497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Empagliflozin reduces left ventricular mass increase and improves cardiomyocyte hypertrophy after 5\/6 nephrectomy"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4997-1257","authenticated-orcid":false,"given":"Xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Wohnhaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Deli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-9426","authenticated-orcid":false,"given":"Nicolas","family":"Schommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5249-4012","authenticated-orcid":false,"given":"Daniel","family":"Duerschmied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaochen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2219-5529","authenticated-orcid":false,"given":"Christoph","family":"Reichetzeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-430X","authenticated-orcid":false,"given":"Mohamed M.S.","family":"Gaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1718-2918","authenticated-orcid":false,"given":"Bernhard K.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8143-0579","authenticated-orcid":false,"given":"Berthold","family":"Hocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118497_bib1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41581-023-00747-4","article-title":"Diagnosis of cardiovascular disease in patients with chronic kidney disease","volume":"19","author":"Zoccali","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.biopha.2025.118497_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101590","article-title":"Left ventricular hypertrophy (LVH) and left ventricular geometric patterns in patients with chronic kidney disease (CKD) stage 2-5 with preserved ejection fraction (EF): a systematic review to explore CKD Stage-wise LVH patterns","volume":"48","author":"Maqbool","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.biopha.2025.118497_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41581-018-0101-8","article-title":"Evolving concepts in the pathogenesis of uraemic cardiomyopathy","volume":"15","author":"Wang","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.biopha.2025.118497_bib4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jchf.2024.02.028","article-title":"Chronic kidney disease progression in heart failure: what we know, don't know, and where to next?","volume":"12","author":"Heerspink","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.biopha.2025.118497_bib5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1042\/CS20171298","article-title":"SGLT2 inhibition and kidney protection","volume":"132","author":"Nespoux","year":"2018","journal-title":"Clin. Sci. (Lond)"},{"key":"10.1016\/j.biopha.2025.118497_bib6","article-title":"Empagliflozin in patients with chronic kidney disease","author":"Group","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118497_bib7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Committees D-CT, and investigators. Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118497_bib8","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.118497_bib9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"And investigators EM-RT. Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118497_bib10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"And investigators EM-PT. Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118497_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"And investigators E-T. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.118497_bib12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study","volume":"9","author":"Requena-Ibanez","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.biopha.2025.118497_bib13","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","article-title":"A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial","volume":"41","author":"Brown","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2025.118497_bib14","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.118497_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118497_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.761855","article-title":"Empagliflozin reduces renal hyperfiltration in response to uninephrectomy, but is not nephroprotective in UNx\/DOCA\/Salt mouse models","volume":"12","author":"Tauber","year":"2021","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2025.118497_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2133\/dmpk.DMPK-12-RG-082","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects","volume":"28","author":"Sarashina","year":"2013","journal-title":"Drug Metab. Pharm."},{"key":"10.1016\/j.biopha.2025.118497_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112606","article-title":"Antifibrotic effects of low dose SGLT2 inhibition with empagliflozin in comparison to ang II receptor blockade with telmisartan in 5\/6 nephrectomised rats on high salt diet","volume":"146","author":"Zeng","year":"2022","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.118497_bib19","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1161\/01.CIR.91.10.2642","article-title":"Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure","volume":"91","author":"Litwin","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.118497_bib20","first-page":"27","article-title":"Assessment of left ventricular structure and function in rats subjected to pressure-overload hypertrophy in time","volume":"67","author":"Stoyanova","year":"2009","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.biopha.2025.118497_bib21","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db13-1029","article-title":"Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen","volume":"63","author":"Kanasaki","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2025.118497_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174715","article-title":"Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-kappaB activation in human endothelial cells and differentiated macrophages","volume":"918","author":"Abdollahi","year":"2022","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118497_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113947","article-title":"Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5\/6-nephrectomy","volume":"156","author":"Lu","year":"2022","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.118497_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4070\/kcj.2019.0296","article-title":"Anti-Inflammatory effect for atherosclerosis progression by Sodium-Glucose cotransporter 2 (SGLT-2) inhibitor in a normoglycemic rabbit model","volume":"50","author":"Lee","year":"2020","journal-title":"Korean Circ. J."},{"key":"10.1016\/j.biopha.2025.118497_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin protects heart from inflammation and energy depletion via AMPK activation","volume":"158","author":"Koyani","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2025.118497_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000343283","article-title":"CD4+ T lymphocytes, especially Th2 cells, contribute to the progress of renal fibrosis","volume":"36","author":"Liu","year":"2012","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.biopha.2025.118497_bib27","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.4049\/jimmunol.1501232","article-title":"Depletion of CD8+ T cells exacerbates CD4+ T cell-induced monocyte-to-fibroblast transition in renal fibrosis","volume":"196","author":"Dong","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2025.118497_bib28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure","volume":"17","author":"Soga","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2025.118497_bib29","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2025.118497_bib30","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.118497_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lfs.2019.05.051","article-title":"Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy","volume":"230","author":"Takasu","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2025.118497_bib32","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) trial","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.118497_bib33","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/01.HYP.34.5.1032","article-title":"Ambulatory blood pressure and metabolic abnormalities in hypertensive subjects with inappropriately high left ventricular mass","volume":"34","author":"Palmieri","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2025.118497_bib34","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1093\/eurheartj\/ehaa530","article-title":"Regression of left ventricular hypertrophy with SGLT2 inhibitors","volume":"41","author":"Paneni","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2025.118497_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0925-4773(00)00341-5","article-title":"Expression patterns of FHL\/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system","volume":"95","author":"Chu","year":"2000","journal-title":"Mech. Dev."},{"key":"10.1016\/j.biopha.2025.118497_bib36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00395-014-0451-8","article-title":"FHL2 expression and variants in hypertrophic cardiomyopathy","volume":"109","author":"Friedrich","year":"2014","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.biopha.2025.118497_bib37","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1096\/fj.12-217018","article-title":"FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2","volume":"27","author":"Okamoto","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2025.118497_bib38","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1128\/MCB.05948-11","article-title":"FHL2 binds calcineurin and represses pathological cardiac growth","volume":"32","author":"Hojayev","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118497_bib39","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1128\/MCB.24.3.1081-1095.2004","article-title":"Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes","volume":"24","author":"Purcell","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118497_bib40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12265-020-10067-8","article-title":"Adult cardiomyocyte proliferation: a new insight for myocardial infarction therapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.biopha.2025.118497_bib41","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1242\/dev.01854","article-title":"Tbx20 is essential for cardiac chamber differentiation and repression of Tbx2","volume":"132","author":"Singh","year":"2005","journal-title":"Development"},{"key":"10.1016\/j.biopha.2025.118497_bib42","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1172\/JCI59472","article-title":"Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte function","volume":"121","author":"Shen","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2025.118497_bib43","doi-asserted-by":"crossref","first-page":"19833","DOI":"10.1073\/pnas.0808705105","article-title":"Transcription factor neuromancer\/TBX20 is required for cardiac function in drosophila with implications for human heart disease","volume":"105","author":"Qian","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118497_bib44","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1093\/hmg\/dds034","article-title":"Dual transcriptional activator and repressor roles of TBX20 regulate adult cardiac structure and function","volume":"21","author":"Sakabe","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2025.118497_bib45","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/CIRCULATIONAHA.115.019357","article-title":"Overexpression of Tbx20 in adult cardiomyocytes promotes proliferation and improves cardiac function after myocardial infarction","volume":"133","author":"Xiang","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.118497_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103031","article-title":"ER stress induces upregulation of transcription factor Tbx20 and downstream Bmp2 signaling to promote cardiomyocyte survival","volume":"299","author":"Das","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118497_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105426","article-title":"Reversal of right ventricular hypertrophy and dysfunction by prostacyclin in a rat model of severe pulmonary arterial hypertension","volume":"23","author":"Vanderpool","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118497_bib48","doi-asserted-by":"crossref","first-page":"C661","DOI":"10.1152\/ajpcell.00177.2023","article-title":"Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench","volume":"325","author":"Chen","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.biopha.2025.118497_bib49","article-title":"Dapagliflozin ameliorates the formation and progression of experimental abdominal aortic aneurysms by reducing aortic inflammation in mice","volume":"2022","author":"Liu","year":"2022","journal-title":"Oxid. Med. Cell Longev."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T02:45:37Z","timestamp":1760582737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225006912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"alternative-id":["S0753332225006912"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118497","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin reduces left ventricular mass increase and improves cardiomyocyte hypertrophy after 5\/6 nephrectomy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118497"}}